Soleno Therapeutics Inc
Soleno Therapeutics Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for rare diseases. Its lead product is VYKAT XR (diazoxide choline) extended-release tablets, an oral treatment for hyperphagia in adults and children with Prader-Willi syndrome, with operations centered in the United States and potential expansion into other major markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueVYKAT XR prescription sales for hyperphagia in Prader-Willi syndrome.
Research and regulatory work supporting future rare-disease therapeutics.
Education, financial assistance, and onboarding support via SOLENO ONE.
Customers
The company sells primarily to specialty pharmacy channels that dispense VYKAT XR pursuant to physician prescriptions. End users are patients with Prader-Willi syndrome, while prescribing decisions are made by physicians and treatment teams managing rare-disease care. Coverage and reimbursement decisions by payers are also important because they influence access and uptake.
Buys VYKAT XR and dispenses it to patients under prescription; critical for commercialization.
Recommend and prescribe VYKAT XR for eligible PWS patients based on clinical need.
Use the therapy to address hyperphagia and related disease burden.
Influence access through formulary placement, coverage, and patient out-of-pocket cost.
Support treatment initiation, adherence, and navigation of access programs.
Strategy
The company’s strategy is centered on building VYKAT XR into a commercial rare-disease product and expanding physician, payer, and patient adoption in the U.S. It is also building the sales, marketing, training, and support infrastructure needed for launch while evaluating whether to commercialize outside the U.S. directly or with partners. Capital access, manufacturing reliability, and reimbursement coverage are central to executing that plan.
The company’s value creation depends on physician adoption, patient access, and prescription growth.
A rare-disease launch requires targeted sales, medical affairs, and support capabilities.
Ex-U.S. markets could broaden the addressable patient base while limiting execution risk through partnerships.
Commercial availability depends on third-party API, CMO, and logistics execution.
Geography
Soleno is headquartered in Redwood City, California and conducts its core commercial and operational activities in the United States. The company stores API and uses third-party manufacturers, logistics providers, and a specialty pharmacy network in the U.S., while also evaluating commercialization options for Europe, Japan, and other major markets. Geography matters because the business depends on U.S. regulatory approval and domestic supply-chain execution, with international expansion still subject to partner and market decisions.
Risks
Soleno is highly dependent on the commercial success of a single approved product, which concentrates execution, reimbursement, and competitive risk. As a rare-disease pharmaceutical company, it also faces regulatory, manufacturing, intellectual property, and market-access risks that can materially affect adoption and supply continuity. International expansion, if pursued, adds partner, regulatory, and country-specific commercialization risk.
- Single-product dependenceImpact: CriticalLikelihood: Medium
Revenue and enterprise value are tied to VYKAT XR adoption and durability.
Exposure: VYKAT XR
- Market acceptance and reimbursement riskImpact: HighLikelihood: Medium
Physicians, patients, caregivers, and payers must accept the therapy for commercial success.
Exposure: U.S. launch
- Manufacturing and supply-chain disruptionImpact: HighLikelihood: Medium
The company relies on third-party CMOs, 3PLs, and external API storage.
Exposure: Commercial supply
- Intellectual property and competitive pressureImpact: HighLikelihood: Medium
Competing PWS therapies or broader appetite-suppression drugs could limit share.
Exposure: Prader-Willi syndrome market
- International regulatory and partner executionImpact: MediumLikelihood: Low
Ex-U.S. commercialization depends on later strategic decisions and local approvals.
Exposure
Accounting
Judgemental itemsReported net sales depend on estimates for rebates, discounts, returns, and copay assistance.
Impact: Can materially change product revenue and gross-to-net deductions
Milestone-based obligations tied to future VYKAT XR sales are remeasured over time.
Impact: Can create volatility in operating expenses and net income
Equity awards are a meaningful expense in a development-to-commercial transition.
Impact: Affects SG&A and R&D expense trends
Investment holdings and warrants require periodic valuation judgments.
Impact: Can affect other income/expense and balance sheet values
Similar listed companies
Publicly listed companies with a comparable business focus.
Soligenix, Inc
SNGX · Pharmaceutical Preparations
Monopar Therapeutics
MNPR · Pharmaceutical Preparations
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers.
Rallybio Corp
RLYB · Pharmaceutical Preparations
Rallybio Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for rare diseases with significant unmet medical need.
X4 Pharmaceuticals, Inc
XFOR · Biological Products, (No Diagnostic Substances)
Rezolute, Inc.
RZLT · Pharmaceutical Preparations
Arrowhead Pharmaceuticals, Inc
ARWR · Pharmaceutical Preparations
Arrowhead Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing RNA interference medicines that silence disease-causing genes.
Last updated: 24/09/2026